FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1976266112> ?p ?o ?g. }

• W1976266112 endingPage "627.e3" @default.
• W1976266112 startingPage "623" @default.
• W1976266112 abstract "Objective To describe the safety and efficacy of rituximab in the treatment of childhood-onset systemic lupus erythematosus (SLE). Study design We conducted a French multicenter retrospective study of childhood-onset SLE treated with rituximab. Results Eleven girls with severe SLE, including 8 girls with class IV or V lupus nephritis, 2 girls with severe autoimmune cytopenia, and 1 girl with antiprothrombin antibody with severe hemorrhage, were treated with rituximab. The mean age at onset of rituximab treatment was 13.9 years. Patients received 2 to 12 intravenous infusions of rituximab (350-450 mg/m2/infusion), with corticosteroids. Six patients also received different standard immunosuppressive agents, including Cyclophosphamide (2 patients). Remission was achieved in 6 of 8 patients with lupus nephritis and in the 2 patients with autoimmune cytopenia. Steroid therapy was tapered in 5 patients who responded to treatment, and low-dose prednisone treatment was maintained in 1 patient. The mean follow-up period was 13.2 months (range, 6-26 months), and remission lasted in all who patients who responded to treatment, except 1 patient who was successfully retreated with a second course of rituximab. Anti-double-stranded DNA antibody levels decreased in 6 of 11 patients, and anticardiolipin antibody levels decreased in 3 of 4 patients. Severe adverse events developed in 5 patients. Effective depletion of peripheral blood B cells was observed in 7 of 8 patients who were examined, and this paralleled the remission. Conclusion Rituximab may be an effective co-therapy; however, further investigations are required because severe adverse events occurred in 45% of the patients in this study. To describe the safety and efficacy of rituximab in the treatment of childhood-onset systemic lupus erythematosus (SLE). We conducted a French multicenter retrospective study of childhood-onset SLE treated with rituximab. Eleven girls with severe SLE, including 8 girls with class IV or V lupus nephritis, 2 girls with severe autoimmune cytopenia, and 1 girl with antiprothrombin antibody with severe hemorrhage, were treated with rituximab. The mean age at onset of rituximab treatment was 13.9 years. Patients received 2 to 12 intravenous infusions of rituximab (350-450 mg/m2/infusion), with corticosteroids. Six patients also received different standard immunosuppressive agents, including Cyclophosphamide (2 patients). Remission was achieved in 6 of 8 patients with lupus nephritis and in the 2 patients with autoimmune cytopenia. Steroid therapy was tapered in 5 patients who responded to treatment, and low-dose prednisone treatment was maintained in 1 patient. The mean follow-up period was 13.2 months (range, 6-26 months), and remission lasted in all who patients who responded to treatment, except 1 patient who was successfully retreated with a second course of rituximab. Anti-double-stranded DNA antibody levels decreased in 6 of 11 patients, and anticardiolipin antibody levels decreased in 3 of 4 patients. Severe adverse events developed in 5 patients. Effective depletion of peripheral blood B cells was observed in 7 of 8 patients who were examined, and this paralleled the remission. Rituximab may be an effective co-therapy; however, further investigations are required because severe adverse events occurred in 45% of the patients in this study." @default.
• W1976266112 created "2016-06-24" @default.
• W1976266112 creator A5001037667 @default.
• W1976266112 creator A5007307581 @default.
• W1976266112 creator A5008567793 @default.
• W1976266112 creator A5036816060 @default.
• W1976266112 creator A5036843379 @default.
• W1976266112 creator A5043841949 @default.
• W1976266112 creator A5045427122 @default.
• W1976266112 creator A5047925131 @default.
• W1976266112 creator A5048508213 @default.
• W1976266112 creator A5055402490 @default.
• W1976266112 creator A5056689111 @default.
• W1976266112 creator A5065464020 @default.
• W1976266112 creator A5071280031 @default.
• W1976266112 creator A5077608212 @default.
• W1976266112 creator A5091090377 @default.
• W1976266112 creator A5091587971 @default.
• W1976266112 date "2006-05-01" @default.
• W1976266112 modified "2023-10-09" @default.
• W1976266112 title "Rituximab therapy for childhood-onset systemic lupus erythematosus" @default.
• W1976266112 cites W1515279716 @default.
• W1976266112 cites W1524173996 @default.
• W1976266112 cites W1562066914 @default.
• W1976266112 cites W1790495991 @default.
• W1976266112 cites W1875806081 @default.
• W1976266112 cites W1963970819 @default.
• W1976266112 cites W1966362133 @default.
• W1976266112 cites W1975743269 @default.
• W1976266112 cites W1979336667 @default.
• W1976266112 cites W1979419663 @default.
• W1976266112 cites W1982948692 @default.
• W1976266112 cites W1989432141 @default.
• W1976266112 cites W2002794826 @default.
• W1976266112 cites W2011158572 @default.
• W1976266112 cites W2017709470 @default.
• W1976266112 cites W2017925927 @default.
• W1976266112 cites W2021257197 @default.
• W1976266112 cites W2036735410 @default.
• W1976266112 cites W2038600011 @default.
• W1976266112 cites W2046468905 @default.
• W1976266112 cites W2060015349 @default.
• W1976266112 cites W2060041600 @default.
• W1976266112 cites W2071499539 @default.
• W1976266112 cites W2072812077 @default.
• W1976266112 cites W2075271226 @default.
• W1976266112 cites W2077409993 @default.
• W1976266112 cites W2083111843 @default.
• W1976266112 cites W2084547554 @default.
• W1976266112 cites W2089016290 @default.
• W1976266112 cites W2096390824 @default.
• W1976266112 cites W2111940985 @default.
• W1976266112 cites W2126641568 @default.
• W1976266112 cites W2126746651 @default.
• W1976266112 cites W2130945067 @default.
• W1976266112 cites W2133880339 @default.
• W1976266112 cites W2148920525 @default.
• W1976266112 cites W2151988044 @default.
• W1976266112 doi "https://doi.org/10.1016/j.jpeds.2006.01.041" @default.
• W1976266112 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/16737873" @default.
• W1976266112 hasPublicationYear "2006" @default.
• W1976266112 type Work @default.
• W1976266112 sameAs 1976266112 @default.
• W1976266112 citedByCount "116" @default.
• W1976266112 countsByYear W19762661122012 @default.
• W1976266112 countsByYear W19762661122013 @default.
• W1976266112 countsByYear W19762661122014 @default.
• W1976266112 countsByYear W19762661122015 @default.
• W1976266112 countsByYear W19762661122016 @default.
• W1976266112 countsByYear W19762661122017 @default.
• W1976266112 countsByYear W19762661122019 @default.
• W1976266112 countsByYear W19762661122020 @default.
• W1976266112 countsByYear W19762661122021 @default.
• W1976266112 countsByYear W19762661122022 @default.
• W1976266112 countsByYear W19762661122023 @default.
• W1976266112 crossrefType "journal-article" @default.
• W1976266112 hasAuthorship W1976266112A5001037667 @default.
• W1976266112 hasAuthorship W1976266112A5007307581 @default.
• W1976266112 hasAuthorship W1976266112A5008567793 @default.
• W1976266112 hasAuthorship W1976266112A5036816060 @default.
• W1976266112 hasAuthorship W1976266112A5036843379 @default.
• W1976266112 hasAuthorship W1976266112A5043841949 @default.
• W1976266112 hasAuthorship W1976266112A5045427122 @default.
• W1976266112 hasAuthorship W1976266112A5047925131 @default.
• W1976266112 hasAuthorship W1976266112A5048508213 @default.
• W1976266112 hasAuthorship W1976266112A5055402490 @default.
• W1976266112 hasAuthorship W1976266112A5056689111 @default.
• W1976266112 hasAuthorship W1976266112A5065464020 @default.
• W1976266112 hasAuthorship W1976266112A5071280031 @default.
• W1976266112 hasAuthorship W1976266112A5077608212 @default.
• W1976266112 hasAuthorship W1976266112A5091090377 @default.
• W1976266112 hasAuthorship W1976266112A5091587971 @default.
• W1976266112 hasConcept C126322002 @default.
• W1976266112 hasConcept C141071460 @default.
• W1976266112 hasConcept C159654299 @default.
• W1976266112 hasConcept C197934379 @default.
• W1976266112 hasConcept C203014093 @default.
• W1976266112 hasConcept C2775915377 @default.

• next